Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 103(17): e37914, 2024 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-38669418

RESUMO

RATIONALE: Primary cardiac angiosarcoma (PCA) is a rare and fatal disease with a poor prognosis. Whether the survival of PCA patients can be prolonged with additional treatment following complete surgical excision is controversial. PATIENT CONCERNS: In this case study, a 52-year-old male complained of chest tightness and pain for 7 days before admission into the hospital. Subsequently, he revisited the hospital because of dizziness and headache. DIAGNOSES: Initially, the patient was diagnosed with PCA in the right atrium by thoracic computed tomography (CT). Palliative resection identified brain, lung, and liver metastases. INTERVENTION: The patient accepted multimodal combination therapy, including first-line chemotherapy and then second-line anlotinib concurrent with brain radiotherapy and immunotherapy. OUTCOME: Although anlotinib combined with brain radiotherapy controlled the growth of intracranial lesions, progression-free survival (PFS) was only 5 months, and the overall survival (OS) was only 12 months. LESSON: The treatment for metastatic PCA needs an in-depth exploration.


Assuntos
Neoplasias Encefálicas , Neoplasias Cardíacas , Hemangiossarcoma , Indóis , Quinolinas , Humanos , Masculino , Pessoa de Meia-Idade , Quinolinas/uso terapêutico , Hemangiossarcoma/terapia , Hemangiossarcoma/patologia , Neoplasias Cardíacas/secundário , Neoplasias Cardíacas/terapia , Neoplasias Encefálicas/secundário , Neoplasias Encefálicas/terapia , Indóis/uso terapêutico , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/terapia , Antineoplásicos/uso terapêutico , Terapia Combinada , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA